微泡
转基因小鼠
外体
L1
神经病理学
细胞生物学
小RNA
免疫沉淀
生物
转基因
分子生物学
化学
医学
病理
生物化学
疾病
基因
作者
Yang Huang,Zongran Liu,Na Li,Chen Tian,Han Yang,Yanfei Huo,Yang Li,Jing Zhang,Zhenwei Yu
摘要
Objective Accumulation of α‐synuclein (α‐syn) in neurons is a prominent feature of Parkinson's disease (PD). Recently, researchers have considered that extracellular vesicles (EVs) may play an important role in protein exportation and propagation, and α‐syn‐containing EVs derived from the central nervous system (CNS) have been detected in peripheral blood. However, mechanistic insights into CNS‐derived EVs have not been well‐described. Methods Likely neurogenic EVs were purified from the plasma of PD patients and healthy controls using a well‐established immunoprecipitation assay with anti‐L1CAM‐coated beads. A Prnp‐SNCA A53T transgenic PD mouse model was used to evaluate the neuronal pathology induced by PD‐derived L1CAM‐purified EVs. EV‐associated microRNA (miRNA) profiling was used to screen for altered miRNAs in PD‐derived L1CAM‐purified EVs. Results PD patient‐derived L1CAM‐purified (likely neurogenic) EVs facilitated α‐syn pathology and neuron loss in Prnp‐SNCA A53T transgenic PD mice. The miRNA, novel_miR_44438, was significantly increased in the PD group, which promoted α‐syn accumulation and neuronal degeneration in a dose‐dependent manner. Novel _miR_44438 directly targets NDST1 mRNA and inhibits the function of heparan sulfate, thus preventing exosome biogenesis and α‐syn release from exosomes. Interpretation Novel_miR_44438 in PD‐derived L1CAM‐purified EVs inhibits the α‐syn efflux from neurons thereby promoting the pathological accumulation and aggregation of α‐syn. ANN NEUROL 2022;92:230–245
科研通智能强力驱动
Strongly Powered by AbleSci AI